ArticlemBio2024
Antiviral mechanisms of guanylate-binding protein 5: versatile inhibition of multiple viral glycoproteins.
Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cell-autonomous immunity as an integrated immune network against bacterial and viral pathogens.Nature microbiology · 2026Review
- The Utility of a Three-gene Host Response to Discriminate Tuberculous Meningitis From Other Infections in Children.The Pediatric infectious disease journal · 2026Article
- Genomic and functional adaptations in the guanylate-binding protein GBP5 highlight specificities of bat antiviral innate immunity.PLoS biology · 2026Article
- Reactive oxygen species promotion drives auranofin's antiviral activity against hepatitis E virus.Journal of virology · 2026Article
- Guanylate-binding protein 5: a promising biomarker and therapeutic target.Infection and immunity · 2025Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Guanylate-binding proteins (GBPs) are interferon-inducible cellular factors known to inhibit a wide variety of pathogens. Humans encode seven GBPs that have functionally diversified to provide broad protection against a variety of bacteria, protozoa, and viruses. Here, we discuss recent data on the mechanisms underlying the broad antiviral activity of GBP5 (H. Veler, C. M. Lun, A. A. Waheed, and E. O. Freed, mBio e02086-24, 2024, https://doi.org/10.1128/mbio.02086-24) and place them in the context of previous studies on the ability of this antiviral factor to impair the function of numerous viral envelope (Env) glycoproteins. We focus on the effects of GBP5 on the glycosylation, proteolytic processing, and anterograde transport of Env and discuss mechanistic interdependencies of these maturation steps. Understanding the induction and action of broadly acting immune factors, such as GBP5, may help develop effective immune-based strategies against numerous pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.